Merck (MRK) re-affirms full year 2012 guidance of EPS of $3.75-3.85, but its Q1 estimate of...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck (MRK) re-affirms full year 2012 guidance of EPS of $3.75-3.85, but its Q1 estimate of $0.95-0.98 is below consensus forecasts, with the company calling out the euro as having a 1-2% negative impact on sales. Shares -1.4% premarket. (PR)